A Phase II open-label single-center study of the clinical activity and safety of the braf-v600 inhibitor vemurafenib (zelboraf) in combination with the b-cell targeting antibody rituximab (mabthera) in previously treated patients with hairy cell leukemia (hcl) carrying the braf-v600e mutation

Trial Profile

A Phase II open-label single-center study of the clinical activity and safety of the braf-v600 inhibitor vemurafenib (zelboraf) in combination with the b-cell targeting antibody rituximab (mabthera) in previously treated patients with hairy cell leukemia (hcl) carrying the braf-v600e mutation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Vemurafenib (Primary) ; Rituximab
  • Indications Hairy cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Results (n=31) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 23 Jan 2017 New trial record
    • 06 Dec 2016 Results (n=22) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top